{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:34:16Z","timestamp":1791052456274,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2011,1,21]],"date-time":"2011-01-21T00:00:00Z","timestamp":1295568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Psoriasis vulgaris is a frequent, chronically relapsing, immune\u2010mediated, systemic disease with characteristic skin changes. Despite the importance of this disease there are currently limited therapeutic options indicating a need for effective, long\u2010lasting treatment strategies with few side effects. The most recent discoveries regarding psoriasis pathogenesis, particularly our results regarding two cytokines \u2013 IL\u201022 and IL\u201020 \u2013 could prove to be the foundation for such therapies. Whereas IL\u201022 is mainly produced by activated T\u2010cell sub\u2010populations (Th22, Th1, Th17), monocytes, dendritic cells and keratinocytes produce IL\u201020. Blood and lesional skin samples from psoriasis patients demonstrate high levels of IL\u201022 and IL\u201020. Interestingly, both cytokines act principally on keratinocytes and do not impact the immune system. Similar to the changes in the psoriasis epidermis these cytokines inhibit the terminal differentiation of keratinocytes although they simultaneously increase their innate defense, mobility, and the production of some chemokines. Some IL\u201022 effects are amplified by TNF\u2010\u03b1, IL\u201017, and IFN\u2010\u03b1. IL\u201022\/IL\u201020 lends the reconstructed epidermis a psoriasis\u2010like appearance with acanthosis, hypogranularity, and hyperkeratosis. In addition, mice that constitutively express high levels of IL\u201022 or IL\u201020 demonstrate a psoriasis\u2010like appearance. A therapy counteracting IL\u201022 and IL\u201020 would be an innovative treatment with the potential for few side effects that would act on the final phase of psoriasis pathogenesis.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2011.07611.x","type":"journal-article","created":{"date-parts":[[2011,1,21]],"date-time":"2011-01-21T08:01:20Z","timestamp":1295596880000},"page":"518-523","source":"Crossref","is-referenced-by-count":13,"title":["Research in practice: IL\u201022 and IL\u201020: significance for epithelial homeostasis and psoriasis pathogenesis"],"prefix":"10.1111","volume":"9","author":[{"given":"Robert","family":"Sabat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,1,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.002"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00629.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.11.001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2006.09.001"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2004.07.007"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535503"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939687"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5397"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0807525"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2010.08.002"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364144"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2006.00516.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-009-0457-0"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-009-0188-x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903907"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.11.5.601"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.10.6.817"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363786"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6364104"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090900"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2011.07611.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2011.07611.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:39:10Z","timestamp":1697452750000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2011.07611.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,21]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1111\/j.1610-0387.2011.07611.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2011.07611.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,21]]}}}